April 29, 2026 4:46pm

Anxiety and fear prods volatility weakening sentiment while tech earnings, econ jitters, oil jumps, Fed rates remain same while anticipating Iran coming actions as the Senate Banking Committee advances Kevin Warsh’s nomination to lead the Fed as Powell conference call leaves Chair while not governor participation

Sector Earnings:

  • MiMedx (MDXG) Q1/26 net loss of -$10.86 M or -$0.07 per share, compared to net income of +$7 M or +$0.05 in Q1/25, revenue of $59 M versus Q1/25 of $72 M, negatively impacted by several Medicare reimbursement changes that went into effect on January 1, most notably a payment cap on allowable reimbursement for skin substitutes on a per square centimeter basis, coupled with lagging marketplace adoption due to uncertainties around these rule changes and cash of $160 M with a runway until 2028
  • Ionis Pharmaceuticals (IONS) Q1/26 net loss of -$93 M or -$0.56 per share versus Q1/25 $147 M or -$0.93, revenue of $246 M versus Q1/25 of $132 M and cash of $1.9 B with a solid runway forward

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

News: Sangamo Therapeutics (SGMO) will transition from trading on The Nasdaq Capital Market to the OTCQB Venture Market on Tuesday, May 5, 2026. This transition follows the receipt by SGMO of a stock notice will be delisted due to non-compliance with bid price requirement. SGMO intends to request a hearing to appeal the delisting determination.

 

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions.  I am more frequently right than consequentially wrong; thus, mostly EARLY in my prognostications!

Wednesday’s RMi Pre-opening: Effects versus affects? … https://www.regmedinvestors.com/articles/14399

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened and some of the whys with the numbers behind

… it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Wednesday: The Dow closed DOWN -279.75 points or -0.57%, the S&P closed DOWN -2.69 points or -0.04% while the Nasdaq closed UP +9.441 points or +0.04%

  • Theme of the session: earnings, econs, the Fed decision and Powell’s status re leaving as oil $ gains

Wednesday (my) 40-company covered sector’s advance/decline line opened negative with 4 incliner, 34 decliners and 2 flats, ending with a negative close of 5 incliners, 33 decliners and 2 flats

  • Sector earnings have begun, with cash positions <so far>to 2028

Henry’omics: We need to more than consider the economic/political environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • The Federal Open Market Committee voted 8-4 to hold rates in a range of 3.5% to 3.75%.

The CBOE Fear (VIX) index, Wednesday closed at 18.50, after Tuesday’s 17.80, Monday’s 18.02, Friday’s 18.70, Thursday’s 19.29 and last Wednesday’s 18.74

Metrics: Wednesday …

  • The RUT was down -19.55 points or -0.71%,
  • The XLV was down -0.99 points or -0.69%,
  • The NBI was down -73.67 points or -1.26%;
  • The XBI was down -2.22 points or -1.69%
  • The IWM was down -1.83 or -0.67%;
  • The IBB was down -2.43 points or -1.45%,
  • The VIX was up +0.67 points or +3.76% at to 18.50
  • The SPX was down -8.01or -0.11% to 7,130.79

 

Q2/26 – 1 holiday, 1 neutral, 10 negative and 8 positive closes

  • Q1 -March – 9 positive and 13 negative closes
  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Wednesday Closing UP (5 of 5) 

  • Ionis Pharmaceuticals (IONS +$3.04 after Monday’s -$0.45),
  • Arrowhead Pharmaceuticals (ARWR +$0.38 after Monday’s -$3.45),
  • Mesoblast (MESO +$0.34)
  • Precigen (PGEN +$0.10 after Monday’s $0.00)
  • Rocket therapeutics (RCKT +$0.05),

Flat (2)

  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus RT (OTCQB: HRGN)

Wednesday’s Closing DOWN (10 of 33): 

  • Vertex (VRTX -$6.90 after Tuesday’s +$4.13 after Monday’s -$4.49),
  • IQVA Holdings (IQV -$2.36 after Tuesday’s -$4.88 after Monday’s +$1.51),
  • Vericel (VCEL -$2.22 after Tuesday’s -$1.27 after Monday’s +$1.28),
  • Capricor Therapeutics (CAPR -$1,52 after Tuesday’s -$1.12),
  • Moderna (MRNA -$1.43 after Tuesday’s -$1.56 after Monday’s -$2.03),
  • CRISPR Therapeutics (CRSP -$1.35 after Tuesday’s +$1.07 after Monday’s +$2.21),
  • uniQure NV (QURE -$1.32 after Tuesday’s +$0.15),
  • Beam Therapeutics (BEAM -$1.18 after Tuesday’s +$11.39 after Monday’s +$2.06),
  • Alnylam Pharmaceuticals (ALNY -$0.92 after Tuesday’s -$6.40 after Monday’s +$2.97),
  • BioLife Solutions (BLFS -$0.91 after Tuesday’s -$0.51 after Monday’s +$0.03),

 

The Bottom Line: More of the … WHY and a lot of what ifs …

Sector equities were back to where they began …

Oil prices rose for another day …

The Fed left its key interest rate unchanged…

Traders waited for earnings as did I …

 

April 5th Week:

  • 4/29 - Wednesday closed negative with 5 incliners, 33 decliners and 2 flats
  • 4/28 – Tuesday closed negative with 17 incliners, 20 decliners and 3 flats
  • 4/27 - Monday closed negative with 13 incliners, 24 decliners and 3 flats

April 4th Week:

  • 4/24 – Friday closed negative with 11 incliners, 27 decliners and 2 flats
  • 4/23 - Thursday closed negative with 7 incliners, 30 decliners and 3 flats
  • 4/22 – Wednesday closed positive with 30 incliners, 9 decliners and 1 flat
  • 4/21 – Tuesday closed negative with 5 incliners, 33 decliners and 2 flats
  • 4/20 - Monday closed negative with 16 incliners, 21 decliners and 3 flats

 

Q1/26 Earnings Release Dates:

  • Alnylam Pharmaceuticals (ALNY) -Thursday, 4/30
  • Moderna (MRNA) - Friday, 5/1
  • IQVIA Holdings (IQV), uniQure NV (QURE), Ultragenyx Pharmaceuticals (RARE) and Supernus Therapeutics (SUPN) – Tuesday, 5/5
  • Sarepta Therapeutics (SRPT) – Wednesday, 5/6
  • Vericel (VCEL) – Thursday, 5/7

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Wednesday: Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY) and Mesoblast (MESO)
  • Tuesday: Vertex (VRTX), AxoGen (AXGN) and Beam Therapeutics (BEAM)
  • Monday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM)
  • Friday: AxoGen (AXGN), IQVA Holdings (IQV) and Capricor Therapeutics (CAPR)

The worst three (3) in the session: Losers’

  • Wednesday: Vertex (VRTX), Moderna (MRNA) and Vericel (VCEL)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), IQVA Holdings (IQV) and Arrowhead Pharmaceuticals (ARWR)
  • Monday: Vertex (VRTX), BioNTech (BNTX) and Compass Therapeutics (CMPX)
  • Friday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Vertex (VRTX),

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.